Investigating the role of TIGIT in kidney injury and recovery
TIGIT in acute kidney injury and repair
This study is looking at how a molecule called TIGIT influences the immune response in people with acute kidney injury, especially those receiving cancer treatments, to help find better ways to protect and heal their kidneys.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11103237 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific immune checkpoint molecule, TIGIT, affects the activation of T cells during acute kidney injury (AKI). By studying the immune response in both animal models and human samples, the researchers aim to uncover the mechanisms by which TIGIT contributes to kidney damage and repair. The approach includes advanced techniques like RNA sequencing and flow cytometry to analyze T cell behavior in the context of kidney injury. The ultimate goal is to develop new therapies that could improve outcomes for patients suffering from AKI, particularly those undergoing cancer treatments that may exacerbate kidney issues.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients who have experienced acute kidney injury, especially those receiving immune checkpoint inhibitors for cancer treatment.
Not a fit: Patients with chronic kidney disease or those not undergoing cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect the kidneys from injury and improve recovery for patients with acute kidney injury.
How similar studies have performed: Previous studies have shown promising results in understanding immune mechanisms in kidney injury, suggesting that this approach could yield valuable insights.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Noel, Sanjeev — Johns Hopkins University
- Study coordinator: Noel, Sanjeev
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.